1. HOME
2023
2023
  • Dec. 2023

    Celltrion Inc. & Celltrion Healthcare Co., Ltd. merger completed

  • Oct. 2023

    Remsima SC (US product name:Zymfentra) received approval by US FDA as novel therapeutics

  • May. 2023

    Yuflyma receives approval by US FDA

2022
2022
  • Sep. 2022

    Vegzelma receives approval by US FDA

  • Aug. 2022

    Vegzelma receives approval by Europe EMA

2021
2021
  • Nov. 2021

    Regkirona receives approval by Europe EMA

  • Feb. 2021

    Yuflyma receives approval by Europe EMA

2020
2020
  • Aug. 2020

    Acquired Primary Care product assets for Asia Pacific markets from Takeda Ltd.

  • Feb. 2020

    Reached KRW 1 trillion in annual sales

2019
2019
  • Nov. 2019

    Remsima SC receives approval by Europe EMA

  • May. 2019

    Expansion of Plant 1 (additional 50,000L) completed

  • Apr. 2019

    Linezolid receives approval by US FDA

2018
2018
  • Dec. 2018

    Herzuma receives approval by US FDA

  • Nov. 2018

    Temixys receives approval by US FDA
    Truxima receives approval by US FDA

  • Feb. 2018

    Herzuma receives approval by Europe EMA

2017
2017
  • Feb. 2017

    Truxima receives approval by Europe EMA

2016
2016
  • Apr. 2016

    Remsima receives approval by US FDA

2015
2015
  • Jun. 2015

    Plant 1 & 2 receive approval by US FDA on all cGMP manufacturing facilities

2013
2013
  • Aug. 2013

    Remsima receives approval by Europe EMA

2012
2012
  • Jul. 2012

    Remsima receives approval by Korea MFDS

2011
2011
  • Oct. 2011

    Plant 2 (90,000L) completed

2008
2008
  • Aug. 2008

    Initial Public Offering (IPO)

2007
2007
  • Dec. 2007

    Plant 1 receives cGMP facility approval by US FDA

2005
2005
  • Jul. 2005

    Plant 1 (50,000L) completed

  • Jun. 2005

    Supply agreement with Bristol-Myers Squibb

2002
2002
  • Feb. 2002

    Celltrion founded